Conditions: Hepatitis C, Chronic
Keywords: hepatitis C ribavirin Hepatitis C-related thrombocytopenia thrombopoietin peginterferon alfa-2b platelets
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 759
Healthy volunteers: no

Brief summary:
The purpose of this study is to assess the ability of eltrombopag to maintain a platelet count sufficient to facilitate initiation of antiviral therapy, to minimise antiviral therapy dose reductions and to avoid permanent discontinuation of antiviral therapy. The clinical benefit of eltrombopag will be measured by the proportion of subjects who are able to achieve a Sustained Virological Response (SVR).

Detailed description:

Arms:
arm 1: active treatment arm arm 2: placebo control arm

Interventions: intervention 1: eltrombopag intervention 2: placebo
Intervention descriptions: intervention 1: double-blind active treatment daily oral administation at dose of 25, 50, 75, or 100 mg intervention 2: double-blind matched placebo control daily oral administration

Protocol document: